---

title: "Soluble IL-2R: A potential therapeutic target for mitochondrial dysfunction in post-COVID fatigue syndrome"
tags:
- ðŸ§ª Biomarker
- ðŸ’Š Treatment
created: '2025-10-13'
published: '2025-10-13'

---


<details>
<summary>Brown et al. (2024)</summary>

- **Authors:** Laura P. Brown, Jai Joshi, Kate Kosmac, Douglas E. Long, Logan Scott, Salim El-Amouri, Ashley A. Montgomery-Yates, Anna G. Kalema, Jamie L. Sturgill, Hemendra Vekaria, Patrick G. Sullivan, Dylan Wilburn, Panagiotis Koutakis, Christine M. Latham, Christopher S. Fry, Philip A. Kern, Benjamin F. Miller, Esther E. Dupont-Versteegden, Ahmed Ismaeel, Kirby P. Mayer, Yuan Wen.
- **Institutes:** List not explicitly provided in the text.
- **Publisher:** Clinical and Translational Medicine
- **Link:** [DOI](https://doi.org/10.1002/ctm2.70507)

</details>


## Summary

This research provides a highly specific molecular link that may explain the debilitating muscle fatigue in post-COVID syndrome (PASC), a condition with similarities to **ME/CFS**. The finding that the inflammatory molecule **sIL2R** is extremely elevated and appears to directly harm muscle mitochondria in the lab suggests a potential root cause for the energy deficits. This is a critical step because it identifies a **specific, measurable factor** that could be targeted with new or existing treatments, such as neutralising antibodies or intravenous immunoglobulin ðŸ’Š (IVIG). If validated, sIL2R could become a valuable objective **biomarker** for diagnosing PASC and monitoring treatment response. The authors also suggest this "sIL2R-mitochondrial dysfunction axis" may explain similar post-viral fatigue conditions, potentially revolutionizing treatment approaches for the broader category of chronic fatigue syndromes.

## What was researched?

This study investigated whether an elevated circulating inflammatory factor, **soluble IL-2 receptor (sIL2R)**, could be the direct cause of muscle mitochondrial dysfunction observed in patients with **Post-COVID Fatigue Syndrome (PASC)**. The core objective was to establish a mechanistic link between systemic immune dysregulation and the muscle pathology characteristic of persistent post-viral fatigue.

## Why was it researched?

Post-COVID fatigue affects millions globally, but the specific factors responsible for muscle dysfunction, despite documented mitochondrial abnormalities, have been speculative. Researchers hypothesized that T-cell-derived inflammatory mediators directly impair muscle mitochondrial function, driving the characteristic persistent fatigue in PASC.

## How was it researched?

This was a prospective, cross-sectional study that analyzed clinical data and tissue samples from a small cohort of **11 PASC patients** experiencing fatigue for more than four weeks and **17 healthy controls**. Methodology included a **6-minute walk test** to assess functional impairment, **muscle biopsies** for histological and biochemical analyses, high-resolution respirometry (HRR) to measure mitochondrial oxygen consumption, and serum analysis to screen for 65 immune mediators. They also performed *in vitro* experiments, treating C2C12 muscle cell cultures directly with sIL2R to assess its effect on mitochondrial function.

## What has been found?

PASC patients showed a statistically significant **16.4% lower average distance** on the 6-minute walk test, alongside histological and biochemical markers of mitochondrial dysfunction, including a **30% reduction** in mitochondrial oxygen consumption driven by Complex I impairment. Serum analysis identified **sIL2R** as the most dramatically elevated factor, showing concentrations up to 5 log-fold higher in PASC patients. *In vitro* experiments confirmed that treating muscle cells with sIL2R directly caused significant reductions in mitochondrial respiration and reduced Complex III protein levels, demonstrating a direct pathogenic effect.

## Discussion

The authors acknowledge that the primary limitation is the **small sample size**, which limits statistical power and generalizability, though the observed effect sizes were large and consistent. They also discuss that the findings are unlikely to be due to simple deconditioning because the patients had preserved muscle mass/strength and a specific pattern of Complex I impairment. The C2C12 cell model is a further limitation, suggesting the need for future studies using primary human muscle cells.

## Conclusion & Future Work

The study concludes that **elevated sIL2R** is a possible cause of mitochondrial dysfunction in post-COVID fatigue, providing a novel molecular mechanism for the condition. These preliminary findings suggest that sIL2R may be a specific circulating factor mediating muscle dysfunction and could serve as a potential, druggable therapeutic target. Future work should focus on validating these results in much larger cohorts and further investigating the exact molecular mechanisms of sIL2R's effects on the muscle cell.
